Posted by Michael Wonder on 17 Nov 2022
Canadian migraine sufferers have a new treatment option - Health Canada approves Ubrelvy (ubrogepant)
16 November 2022 - Ubrelvy is the first and only oral CGRP receptor antagonist (gepant) approved by Health Canada for the acute treatment of migraine.
AbbVie announced today that Health Canada has approved Ubrelvy (ubrogepant ) for the acute treatment of migraine, with or without aura, in adults.
